Most Recent
Danish pharmaceutical giant Lundbeck secured $51.7 million in settlements to end infringement litigation with three generic makers over its patent for the top-selling Lexapro, the company has revealed.
Otsuka Pharmaceuticals and Bristol Myers-Squibb can retain their defences in an ongoing patent dispute over antipsychotic drug Abilify, after the Federal Court dismissed a strike out bid by the Commonwealth of Australia over the allegedly "inconsistent" pleadings.
AFT Pharmaceuticals has filed a lawsuit seeking to pre-empt competitor Reckitt Benckiser from pursuing a lawsuit against it over recent ads for its painkiller Maxigesic.
Ramsay Health Care has denied its conduct towards a group of surgeons seeking to open a rival clinic in Coffs Harbour, NSW was anti-competitive or a misuse of market power, telling the court on the first day of trial that the venture was doomed to fail.
The Full Court has denied a request by Sanofi that it review a judge's refusal to block Alphapharm from listing its Semglee insulin injector pen on the PBS, calling the pharmaceutical giant's appeal "misconceived".
The stakes will be high for the ACCC when the trial kicks off Monday in its case against Ramsay Health Care alleging the hospital giant misused its market power and engaged in exclusive dealing, after the competition regulator came up short in its last big misuse of market power case against pharmaceutical giant Pfizer.
New Zealand-based medical device maker Fisher & Paykel and US-based ResMed have agreed to resolve all disputes between them over patents for devices used to treat sleep apnea.
The former chief financial officer for Calvary Health Care has been convicted and sentenced after pleading guilty to making false records that misstated the company's revenue by millions of dollars.
The Full Federal Court will issue its judgment Friday in French pharmaceutical giant Sanofi's challenge to a judge's refusal to block Alphapharm from listing an insulin injector pen on the PBS, just two weeks after the court heard arguments in the appeal.
Generic drug maker Sandoz must pay $26.34 million to Danish pharmacuetical giant Lundbeck and a subsidiary for infringing the Australian patent behind the blockbuster antidepressant Lexapro, a judge has found.